Core Viewpoint - Suzhou Beikang Medical has received approval from the National Medical Products Administration (NMPA) for its Gems culture medium (embryo handling liquid VitBase), marking a significant milestone in the localization of reproductive liquids in China and demonstrating the company's full industry chain capability from international acquisition to domestic registration [1][3][4]. Group 1: Product Approval and Significance - The approval of VitBase is the first registration certificate among the 11 products in the GEMS series, laying the foundation for the subsequent localization of the entire product line in China [4]. - This approval reflects the national support for the innovative transformation of overseas medical products and positions Beikang Medical as one of the few companies globally with CE, FDA, and TGA certifications for reproductive liquids [3][4]. Group 2: Market Impact and Benefits - The introduction of the Gems culture medium is expected to enhance supply chain security, reduce reliance on imports, and promote a more reasonable pricing system, benefiting more patients [4]. - The product is based on over 30 years of clinical experience from the globally recognized Sydney IVF center, ensuring high product quality while improving accessibility and supply chain reliability [3][4]. Group 3: Future Outlook - Beikang Medical aims to provide a more stable culture environment for embryos and improve the success rates of IVF in China through the localization of Gems culture medium [8]. - The company plans to continue developing and registering high-end reproductive medical products, gradually achieving full-chain domestic substitution [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Suzhou Basecare Medical Corporation Limited 蘇 州 貝 康 醫 療 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2170） 董事會會議通告 蘇州貝康醫療股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會 會議將於2025年8月29日（星期五）舉行，藉以（其中包括）考慮及批准本公司及 其附屬公司截至2025年6月30日止六個月之中期業績及其發佈，並考慮建議派 發中期股息（如有）。 承董事會命 蘇州貝康醫療股份有限公司 董事長兼總經理 梁波博士 中國蘇州，2025年8月19日 截至本公告日期，董事會由執行董事梁波博士、孔令印先生及姜雋超女士；非執行董事趙業 先生、王偉鵬先生及凌洋先生；以及獨立非執行董事康熙雄博士、林兆榮先生及楊樹標博士 組成。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 蘇州貝康醫療股份有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02170 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 82,713,835 | RMB | | 1 | RMB | | 82,713,835 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 82,713,835 | RMB | | 1 | RMB | | 82,713,835 | | 2. 股份分類 | 普通股 | ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

Core Viewpoint - The announcement of a new childcare subsidy policy in China is expected to significantly benefit the infant and child-related stocks, leading to notable increases in their market performance [1]. Group 1: Stock Performance - H&H International Holdings (01112) rose by 4.28%, trading at 11.7 HKD [1] - Jinxin Fertility (01951) increased by 3.73%, trading at 3.34 HKD [1] - Beikang Medical-B (02170) saw a rise of 2.41%, trading at 2.98 HKD [1] - China Feihe (06186) grew by 1.7%, trading at 4.79 HKD [1] Group 2: Policy Announcement - The State Council Information Office will hold a press conference on July 30, 2023, to discuss the childcare subsidy system and related measures [1]. - Starting from January 1, 2025, families will receive an annual subsidy of 3600 CNY for each child until they reach three years old, regardless of whether they have one, two, or three children [1]. - For children born before January 1, 2025, and under three years old, the subsidy will be calculated based on the number of months eligible [1]. Group 3: Market Analysis - According to CITIC Securities, four sectors are expected to benefit the most: dairy products, maternal and infant retail, infant products, and postpartum care services [1]. - The market size for infant formula is projected to grow from 200 billion CNY to 300 billion CNY by 2025 [1]. - Maternal and infant retail is expected to maintain a growth rate of over 20% [1]. - The infant products market will continue to expand due to consumption upgrades [1]. - Postpartum care services are anticipated to be the fastest-growing segment, with an annual growth rate exceeding 30% [1].

昨日呈现高开低走的三胎概念股再起升势，其中，H&H国际控股涨4.28%，锦欣生殖涨近4%，贝康医 疗涨2.4%，中国飞鹤涨1.7%，蒙牛乳业跟涨。 | 代码 | 名称 | 最新价 | 涨跌幅 ▽ | | --- | --- | --- | --- | | 01112 | H&H国际控股 | 11.700 | 4.28% | | 01951 | 锦欣生殖 | 3.340 | 3.73% | | 02170 | 贝康医疗-B | 2.980 | 2.41% | | 06186 | 中国飞鹤 | 4.790 | 1.70% | | 00151 | 中国旺旺 | 5.780 | 1.05% | | 02319 | 蒙牛乳业 | 17.020 | 0.71% | 消息面上，7月28日，中办、国办印发《育儿补贴制度实施方案》，明确对3周岁以下婴幼儿按每孩每年 3600元标准发放补贴。浙商证券发布研究报告称，国家育儿补贴制度实施方案于2025年7月28日公布， 面向育儿家庭全国范围全面直接发放现金补贴，有助于缓解家庭养育压力。随着生育补贴政策实施落 地，有望改善市场预期，母婴消费产业链或更多获益，汽车、餐饮等领域也可能迎来 ...

中信证券分析指出，乳制品、母婴连锁、婴幼儿用品、产后护理服务四大方向受益最为明显。其中，婴 幼儿配方奶粉作为刚需产品，市场规模有望从目前的2000亿元增长至2025年的3000亿元；母婴连锁零售 预计保持20%以上的增速；婴幼儿用品市场随着消费升级将持续扩容；产后护理服务则有望成为增长最 快细分领域，年增速或超过30%。 婴童概念股多数高开，截至发稿，H&H国际控股(01112)涨4.28%，报11.7港元；锦欣生殖(01951)涨 3.73%，报3.34港元；贝康医疗-B(02170)涨2.41%，报2.98港元；中国飞鹤(06186)涨1.7%，报4.79港元。 消息面上，据国新办网站消息，国务院新闻办公室将于7月30日(星期三)下午2时举行新闻发布会，请国 家卫生健康委副主任郭燕红和财政部、国家医保局、全国总工会有关负责人介绍育儿补贴制度及生育支 持措施有关情况，并答记者问。此前，国家育儿补贴制度实施方案公布，从2025年1月1日起，无论一 孩、二孩、三孩，每年均可领取3600元补贴，直至年满3周岁。其中，对2025年1月1日之前出生、不满3 周岁的婴幼儿，按应补贴月数折算计发补贴。 ...

Group 1 - The core viewpoint of the article highlights the positive market response of baby and child concept stocks following the announcement of a new childcare subsidy policy by the Chinese government [1] - H&H International Holdings (01112) rose by 4.28% to HKD 11.7, Jinxin Fertility (01951) increased by 3.73% to HKD 3.34, Beikang Medical-B (02170) gained 2.41% to HKD 2.98, and China Feihe (06186) saw a rise of 1.7% to HKD 4.79 [1] - The new childcare subsidy policy will provide an annual subsidy of CNY 3,600 for each child until the age of three, starting from January 1, 2025, benefiting all families regardless of the number of children [1] Group 2 - According to CITIC Securities, four sectors are expected to benefit significantly from the new policy: dairy products, maternal and infant chain retail, baby products, and postpartum care services [1] - The market size for infant formula milk is projected to grow from CNY 200 billion to CNY 300 billion by 2025, indicating a strong demand for essential products [1] - Maternal and infant chain retail is expected to maintain a growth rate of over 20%, while the baby products market will continue to expand due to consumption upgrades [1] - Postpartum care services are anticipated to be the fastest-growing segment, with an annual growth rate potentially exceeding 30% [1]

Group 1 - The national childcare subsidy policy will be implemented starting January 1, 2025, providing annual subsidies of 3,600 yuan per child for infants under three years old [1] - The policy marks a shift from previous regional subsidies focused on families with two or more children to a nationwide coverage, which is expected to boost consumer sentiment in the maternal and infant market [2] - The introduction of the subsidy is anticipated to support the assisted reproductive market, providing assistance to families wishing to have children [2] Group 2 - The macro policy benefits indicate a clear growth direction for the industry, with subsidies and incentives elevating the assisted reproductive sector to a core component of national population strategy [2] - The integration of assisted reproduction into health insurance is expected to lower the cost barrier for treatments, thereby increasing demand for related medical services and products [2] - Companies like Beikang Medical are positioned to benefit from these policies, with their strategic focus aligning with the growing market demand [2][5] Group 3 - Beikang Medical is leveraging its technological and product advantages to capture market opportunities in underdeveloped segments, such as genetic testing and male reproductive health products [2][5] - The company is expected to lead the domestic market in assisted reproduction, benefiting from both policy support and its established market position [5] - Beikang Medical's valuation may increase as the assisted reproductive industry experiences rapid growth, supported by favorable policies [5] Group 4 - As of July 28, 2025, Beikang Medical's PS (TTM) is 2.447, indicating potential undervaluation compared to its technological barriers and industry leadership [6] - The company is projected to achieve significant revenue growth, with forecasts suggesting revenues could reach 400 million yuan by 2026, leading to a market valuation between 1.6 billion and 2.4 billion yuan [6] - The new national fertility policy, along with local support measures, presents a historic opportunity for the assisted reproductive industry, with Beikang Medical positioned to capitalize on this growth [6]

Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The company is a leader in the high-end domestic skincare market in China, focusing on anti-wrinkle and firming skincare products, with its flagship brand "Lin Qing Xuan" offering high-end skincare solutions based on natural camellia ingredients [3][8] - The market for skincare products in China is projected to reach CNY 688.6 billion by 2024, with a compound annual growth rate (CAGR) of 6.8% from 2019 to 2024, and an expected CAGR of 8.6% from 2024 to 2029 [4][37] - The facial essence oil category, driven by the "oil-based skincare" trend, is expected to grow significantly, with a market size of CNY 5.3 billion in 2024 and a CAGR of 42.8% from 2019 to 2024 [4][37] - The company has seen substantial revenue growth, with a projected revenue of CNY 1.21 billion in 2024, representing a 50.3% year-on-year increase [18] Company Overview - The company has established itself as a rare high-end domestic skincare brand, with its camellia essence oil being the top-selling product in the facial essence oil category for 11 consecutive years [3][8] - The company has a balanced distribution of online and offline channels, with online sales growing significantly, contributing to overall revenue growth [5][25] - The company has a strong presence in the high-end anti-wrinkle skincare market, ranking first among domestic brands and being the only domestic brand in the top ten [3][8] Market Trends - The demand for anti-wrinkle and firming skincare products is high, with a projected market size of CNY 119.8 billion in 2024 and a CAGR of 15.0% from 2019 to 2024 [49] - The high-end skincare segment is expected to grow faster than the mass market, with a projected CAGR of 8.9% from 2019 to 2024 [43] Financial Performance - The company's gross margin has been consistently high, with projections of 82.5% in 2024, and a significant improvement in net profit margin from -0.9% in 2022 to 15.4% in 2024 [88] - The company has achieved a turnaround in profitability, with a net profit of CNY 187 million in 2024, representing a 121.1% year-on-year increase [18][88] Distribution Channels - The company has expanded its offline presence, with a total of 506 stores by the end of 2024, primarily located in shopping malls [78] - Online sales have become the dominant revenue source, accounting for 59.1% of total revenue in 2024, with significant growth in both direct sales and sales through online retailers [25][74] Product Strategy - The company's primary product category is facial essence oil, which has seen a revenue increase from CNY 218 million in 2022 to CNY 448 million in 2024, with a growing market share [66][70] - The company has successfully positioned its camellia essence oil as a leading product in the market, with cumulative sales exceeding 30 million bottles by the end of 2024 [66]